Research programme: VLA-4 antagonists - Biogen IdecAlternative Names: VLA-4 antagonists research programme - Biogen Idec
Latest Information Update: 04 Mar 2009
At a glance
- Originator Biogen Idec
- Mechanism of Action Integrin alpha4beta1 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation; Multiple sclerosis
Most Recent Events
- 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
- 10 Jul 2002 This programme is still in active development
- 12 Oct 1999 Preclinical development for Inflammation in USA (PO)